COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 30 of 63 for:    Lixisenatide

Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM) (LixilanOne CAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03767543
Recruitment Status : Active, not recruiting
First Posted : December 6, 2018
Last Update Posted : April 20, 2020
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : November 2020